BiotechTube

PRGN-2009 plus Pembrolizumab + Pembrolizumab alone

Phase 2Recruiting
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cervical Cancer

Conditions

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer

Trial Timeline

Mar 21, 2025 → Jan 30, 2028

NCT ID
NCT06157151

About PRGN-2009 plus Pembrolizumab + Pembrolizumab alone

PRGN-2009 plus Pembrolizumab + Pembrolizumab alone is a phase 2 stage product being developed by Precigen for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06157151. Target conditions include Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06157151Phase 2Recruiting

Competing Products

20 competing products in Cervical Cancer

See all competitors
ProductCompanyStageHype Score
ABP-450AEON BiopharmaPhase 2
44
ABP-450 + PlaceboAEON BiopharmaPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
52
Amolimogene + AmolimogeneEisaiPhase 2/3
65
BOTULINUM TOXIN TYPE BEisaiPhase 2
52
Gemzar (gemcitabine)Eli LillyPhase 3
77
PemetrexedEli LillyPhase 2
52
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
52
camrelizumab； famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
52
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
52
VolrustomigAstraZenecaPhase 3
77
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
77
VolrustomigAstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52

Other Products from Precigen

Zopapogene imadenovec (Zopa)Approved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2Phase 1/2
36
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePhase 1/2
36
INXN-4001Phase 1
28
Fludarabine + Cyclophosphamide + PRGN-3007Phase 1
28